The prognostic impact of PGRMC1 is largely unexplored in ovarian cancer, but high serum-levels of relaxin-2 have been associated with tumor progression and adverse survival in several malignancies [24–26], including ovarian cancer [27]. This evidence concerns the gene RLN2 and ovarian carcinoma.